• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

In expanded deal with India, Novax aims for 2 billion COVID-19 doses

|

New Delhi, Sep 16: Novax Inc, the US drug developer said that it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under and agreement with the Serum Institute of India.

Novax had in August signed a deal with Serum Institute to produce a minimum of one billion doses of its vaccine candidate.

In expanded deal with India, Novax aims for 2 billion COVID-19 doses

Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVX CoV2373 as part of the expanded agreement. The Novax vaccine is currently in the mid-stage trials after an early stage showed it produced highest levels of antibodies against the coronavirus. The company has plant to begin late stage trials in the third quarter.

Serum Institute gets DCGI nod to resume clinical trial of AstraZeneca vaccine

Novax had said last month that it will supply 60 million doses of its vaccine candidate to the UK beginning as early as the first quarter of 2021. The company is also preparing to deliver 100 million doses to the United States by January. It was awarded 1.6 billion USD for its potential vaccine. Further supply agreements were also signed with Japan and Canada.

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X